TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Estimated Ratio of Full Self-efficacy to Grow F&V at School
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absolute Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Parenteral Support (PS) Volume at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Achieved 100 Percent (%) Reduction in Complete Weaning of Parenteral Support (PS) Volume at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in vital signs as measured by heart rate, blood pressure and oral temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in physical exam measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Distance Uncorrected Visual Acuity Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychosocial progress
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Morphologic assessment of GL-3 inclusions in the capillary endothelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With Active Cytomegalovirus (CMV) Infection Within 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With CMV Disease Within 12 Months Including CMV Syndrome and Tissue Invasive Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Graft Loss at Month 84
Endpoint domain: Mortality/survival
Primary endpoint: Number of Putative Sites of Metastatic Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Location of Putative Sites of Metastatic Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in levels of salivary TNF alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Expression levels of target proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 6 month local control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3-4 liver function test (LFT) elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Glycemic control assessed by HbA1C level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: C-11 acetate uptake and retention in prostate tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Levels of FAS expression in tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reaction time (msec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: errors of omission (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: errors of commission (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fibroid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain white matter development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Esophageal Lesions Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of downstaging after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of Worst Itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Short-term Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Re-interventions Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Patients Who Were Cured
Endpoint domain: Mortality/survival
Primary endpoint: Time Until the Maximum Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Grade 2 or Higher Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oropharyngeal sensation perturbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity score (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in gene and protein expression due to acid exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in local impedance of the esophageal mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CLN2 Disease Severity Scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroretinogram (ERG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Assessment, Wechsler Intelligence Scale for Children version 4 (WISC-IV)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Fatigue Scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: body composition change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of mothers who discontinued 1st treatment choice prior to delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of mothers engaged in treatment at delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of mother-child dyads with delivery complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: TLR4, CD40L and P-selectin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Platelet leukocyte aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cognitive skill as assessed via eye tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Reactivity (Crying) assessed by the Face to Face/Still Face Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of renal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Large Airway Pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: High Peak Airflows
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of pre-extubation atelectasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Chronic Prostatitis Symptom Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum ceramides level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Remission from proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence of symptomatic CTEPH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of DLT(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Duration of ICU/hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Culture conversion from positive to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Post-exercise energy compensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of the CINSARC signature to identify surgical resectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Compliance to overall inpatient treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Exacerbation of chronic hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Grade 2 or higher Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Interleukin-1B mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: H+,K+-ATPase mRNA expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Doppler correlation with placental pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: CK
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GOLD stages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Loss of Endothelial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of care goals met
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Product acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from the baseline serum uncoupling protein 1 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from the baseline serum irisin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients opting out of routine care - no intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients opting out of routine care - no CPR
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment Discontinuations Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Target Lesion Failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: QRS frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of clinical states
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GMT of HI antibody titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Whole Brain PBR28 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With no Evidence of >30s Recurrent Atrial Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decrease of pain impact on daily life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Recurrent bleeding within 30 days after initial endoscopy
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters (AUC & Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Disinhibition Domain of the Neuropsychiatric Inventory (NPI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in ASIA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle Sympathetic Nerve Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Drape Adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Heart Rate Recovery (HRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart Rate Fragmentation (HRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in Left-ventricular End Systolic Volume Index (LVESVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC)_0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pharmacokinetics measured at various time points after dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adult BMI change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of the Clinical Response at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with undetectable plasma HIV-1 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of subjects with thermal-related skin events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of Patients with ≥ 20% Decrease in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Investigator's Global Assessment of Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5-year disease-specific mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients with B2AD gene polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wong-Baker Faces Pain Rating Scale (PRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face, Legg, Cry, Consolability Scale (FLACC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Phosphorus change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving a Physician's Global Assessment (PGA) Score of Cleared (0) or Minimal (1)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inflammation Grade at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PCr Concentration (at rest)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Paracentesis Induced Circulatory Dysfunction (PICD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time From Study Drug Initiation to Tracheal Extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Neonatal Infections With a S. Aureus Strain
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PHQ-9 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean difference of single nucleotide polymorphism of VDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perineal pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periapical Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival of IPF
Endpoint domain: Mortality/survival
Primary endpoint: Five Facet Mindfulness Questionnaire-15 (FFMQ-15)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Overall Comfort Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline of Central Systolic Blood Pressure (SBP) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete Response Rate (CR+CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral embolic load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patellar tendon regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Spontaneous Bowel Movement (CSBM) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tumor response (dose expansion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Who Achieved Intact Parathyroid Hormone (iPTH) Levels Within the Target Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to Achieve Target Range of Intact Parathyroid Hormone (iPTH) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall response rate assessed by tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area under curve (AUC) of Amitriptyline and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum concentration (Cmax) of Amitriptyline and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in energy availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial glucose AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absence of Symptomatic Anastomotic Leakage at Day 30
Endpoint domain: Adverse events/effects
Primary endpoint: Time-to-complete-healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Chloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Degree of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Achieving Global Lipid Targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Thermoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Heat Pain Tolerance Test (HPTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Intensity of the UVB-induced Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity of the CLM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of the CLM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of the CLM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant's response to vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality of ARDS patients
Endpoint domain: Mortality/survival
Primary endpoint: Rate of major molecular remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: English proficiency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Children's physical health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Normalized Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diaphragm muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Purdue Pegboard Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mitochondrial oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial production of reactive oxygen species
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Colony Forming Units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Forced expiratory volume in 1-second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Life (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease burden comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction rate of Minimal residual disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Superficial Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 of Vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 of Self-assessment of the Most Bothersome Symptom Dyspareunia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing